Illarionov
Mikhail Illarionov, Osaka-Shi JP
Patent application number | Description | Published |
---|---|---|
20110254623 | DISTORTION COMPENSATION CIRCUIT - Disclosed is a distortion compensation circuit that efficiently compensates for distortion. A distortion compensation circuit ( | 10-20-2011 |
20120300824 | PEAK POWER SUPPRESSING CIRCUIT AND COMMUNICATION DEVICE HAVING THE SAME - An object of the present invention is to provide a peak power suppressing circuit | 11-29-2012 |
20120321014 | SIGNAL PROCESSING CIRCUIT AND COMMUNICATION DEVICE HAVING THE SAME - An object of the present invention is to appropriately limit an amplitude of an IQ baseband signal having different average powers for respective frequency bands B | 12-20-2012 |
Petr Illarionov, Birmingham GB
Patent application number | Description | Published |
---|---|---|
20130039886 | BETA-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY - β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of α-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising β-mannosylceramide, as well as methods of treatment of tumors are also provided. | 02-14-2013 |
20140301996 | METHODS FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES - The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived from | 10-09-2014 |
Petr A. Illarionov, Birmingham GB
Patent application number | Description | Published |
---|---|---|
20140348786 | BETA-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY - β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of α-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising β-mannosylceramide, as well as methods of treatment of tumors are also provided. | 11-27-2014 |